Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

475838 Mifepristone - CAS 84371-65-3 - Calbiochem

A cell-permeable synthetic steroid that acts as a potent antagonist of progesterone and glucocorticoid receptors.

Mifepristone - CAS 84371-65-3 - Calbiochem: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: (11β,17β)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, RU-486

Primary Target: Progesterone and glucocorticoid receptors
475838
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
84371-65-3C₂₉H₃₅NO₂

Products

Número de referenciaEmbalaje Cant./Env.
475838-50MG Ampolla de plást. 50 mg
Description
OverviewA cell-permeable synthetic steroid that acts as a potent antagonist of progesterone and glucocorticoid receptors. Inhibits P-glycoprotein (P-gp) function and down-modulates P-gp mediated drug resistance. Displays anti-angiogenic effects and suppresses vascular endothelial growth factor (VEGF) production. Regulates the expression of Fas and FasL in mouse endometrium and TRAIL in prostate cancer cells. As an antioxidant, it offers neuroprotection against controlled cortical impact (CCI) in CA1 pyramidal cells, as well as Aβ-, H2O2-, and glutamate-induced injury to mouse hippocampal HT22 cells.
Catalogue Number475838
Brand Family Calbiochem®
Synonyms(11β,17β)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, RU-486
References
ReferencesMcCullers, D.L., et al. 2002. Neuroscience 109, 219.
Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.
Product Information
CAS number84371-65-3
ATP CompetitiveN
FormYellow solid
Hill FormulaC₂₉H₃₅NO₂
Chemical formulaC₂₉H₃₅NO₂
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetProgesterone and glucocorticoid receptors
Purity≥99% by titration
Physicochemical Information
Cell permeableY
ContaminantsSteroid substances: ≤0.1%
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSKG2955000
Safety Information
R PhraseR: 60-61

May impair fertility.
May cause harm to the unborn child.
S PhraseS: 22-36/37/39-45

Do not breathe dust.
Wear suitable protective clothing, gloves and eye/face protection.
In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Carcinogenic / Teratogenic
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
475838-50MG 04055977184976

Documentation

Mifepristone - CAS 84371-65-3 - Calbiochem Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Mifepristone - CAS 84371-65-3 - Calbiochem Certificados de análisis

CargoNúmero de lote
475838

Referencias bibliográficas

Visión general referencias
McCullers, D.L., et al. 2002. Neuroscience 109, 219.
Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.

Folleto

Cargo
Alzheimer's Disease Brochure & Technical Guide
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision28-April-2009 RFH
Synonyms(11β,17β)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, RU-486
DescriptionA cell-permeable, synthetic steroid that acts as a potent antagonist of progesterone and glucocorticoid receptors. Reported to inhibit P-glycoprotein (P-gp) function and down-modulate P-gp mediated drug resistance. Also displays anti-angiogenic effects and suppresses vascular endothelial growth factor (VEGF) production. Shown to regulate the expression of Fas and FasL in mouse endometrium and of TRAIL in prostate cancer cells. As an antioxidant, it is reported to offer neuroprotection against controlled cortical impact (CCI) in CA1 pyramidal cells, as well as Aβ-, H2O2-, and glutamate-induced injury to mouse hippocampal HT22 cells.
FormYellow solid
Intert gas (Yes/No) Packaged under inert gas
CAS number84371-65-3
RTECSKG2955000
Chemical formulaC₂₉H₃₅NO₂
Structure formulaStructure formula
Purity≥99% by titration
ContaminantsSteroid substances: ≤0.1%
SolubilityEthanol (10 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Carcinogenic / Teratogenic
Merck USA index14, 6186
ReferencesMcCullers, D.L., et al. 2002. Neuroscience 109, 219.
Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.